Sign in
Active, not recruitingPhase 3

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Key facts

Who runs it
Ionis Pharmaceuticals, Inc.
Where
Boca Raton, Huntington Beach, Kansas City, New York, Park Ridge, and Philadelphia, United StatesSee the 7 sitesAlso in 10 other countries, 20 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
60 people enrolled
Started
18 Nov 2021
Expected to end
Feb 2028
Type of study
Interventional
Treatments tested
  • Olezarsen
Record updated
12 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Satisfactory completion of treatment with olezarsen in the index study (ISIS 678354-CS3, last dose as scheduled at Week 49) with an acceptable safety profile, per Investigator judgement

Who cannot take part

  • Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the patient participating in or completing the study, including need for treatment with medications disallowed in the index study (ISIS 678354-CS3)

Where in United States

Also in 10 other countries, 20 sites

  • Excel Medical Clinical Trials, LLCBoca Raton, United States
  • Diabetes/Lipid Management & Research CenterHuntington Beach, United States
  • University of Kansas Medical Center (KUMC)Kansas City, United States
  • CTSI Investigational PharmacyNew York, United States
  • Milstein HospitalNew York, United States
  • Department of PharmacyPark Ridge, United States
  • IDS CentralPhiladelphia, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.

The group in the trial

  • OlezarsenTreatment being tested

    Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 153.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Record updated
12 December 2025